Acta Pharma Reports
[ISSN: 3041-5381 (Online)]
Frequency 2 issues per year
Language-English
Subject: Pharmaceutical Sciences
Starting Year 2022
Format of publication –Online
Country of Publication-Belgium
Acta Pharma Reports ISSN 3041-5381 is a biannually peer-reviewed multi-disciplinary pharmaceutical publication to serve as a means for scientific information exchange in the international pharmaceutical forum. It accepts novel findings that contribute to advancement of scientific knowledge in pharmaceutical fields that not been published or under consideration for publication anywhere else for publication in JRPS as original research article and all aspects of pharmaceutical sciences consisting of medicinal chemistry, molecular modeling, drug design, pharmaceutics, bio-pharmacy, pharmaceutical nanotechnology, pharmacognosy, natural products, pharmaceutical biotechnology, pharmacology, toxicology and clinical pharmacy.
The journal is registered with the following abstracting partners:
American Society of Health System Pharmacists, Baidu Scholar, Previews, CNKI (China National Knowledge Infrastructure Ex Libris – Primo Central, Google Scholar, Hinari, Infotrieve, National Science Library, ProQuest, TDNet, Wanfang Data
Submit Proposal
Acta Pharma Reports [ISSN 3041-5381] runs special issues to create collections of papers on specific topics. The aim is to build a community of authors and readers to discuss the latest research and develop new ideas and research directions. Special Issues are led by Guest Editors who are experts in the subject and oversee the editorial process for papers. Papers published in a Special Issue will be collected together on a dedicated page of the journal website.
Article Processing Charge (APC): USD 100 (applicable only after acceptance of the manuscript).
For any inquiries related to a Special Issue, please contact the Editorial desk at editor@pharma.researchfloor.org or submission@pharma.researchfloor.org
Discover the Latest in Pharmaceutical Sciences with the Journal of Acta Pharma Reports. Explore Groundbreaking Research, Innovation, and Insights. Stay Ahead in Pharma’s Dynamic Landscape.
1. Introduction Use up and down arrow keys to resize the meta box pane. Use up and down arrow keys to resize the meta box pane. Use up and down
INTRODUCTION 1.1 Overview of Sickle Cell Anemia Despite decades of advancements in biomedicine, sickle cell anemia (SCA), one of the most researched monogenic illnesses, continues to be a significant health
Introduction Pharmaceutical effluents have become important environmental sources of antibiotic contamination because manufacturing plants and related discharge streams can release active antimicrobial residues, resistant bacteria, and resistance genes into receiving
Introduction Ebola virus (EBOV) and Lassa virus (LASV) pose immediate, severe threats to human life and public health, as demonstrated by ongoing outbreaks of EBOV disease (EVD) in the Democratic
Introduction Autoimmunity arises when T cells, B cells, or both become inappropriately activated and cause damage to one or more organs [1]. Under normal conditions, the immune system distinguishes self-components
1. Introduction “Nano” is a thousand millionth of a metre. The branch of nanotechnology is the name given to the science that studies structures and molecules on a nanoscale level
Introduction Deep vein thrombosis (DVT) is a major component of venous thromboembolism (VTE), which remains a major cause of cardiovascular morbidity and mortality worldwide. For a long time, oral anticoagulation
1. Introduction The effectiveness of drug therapy varies substantially among individuals due to differences in genetic makeup, environmental exposures, lifestyle factors, age, sex, and disease characteristics. Conventional therapeutic approaches typically
1. Introduction N- (Substituted Aryl) Acryloyl Theophylline Derivatives are a class of compounds that involve the combination of theophylline, a known methylxanthine derivative, with acryloyl groups and substituted aryl groups.
